China Biologic Products, Inc., through its subsidiaries, engages in the research, development, manufacturing, and sale of plasma-based pharmaceutical products. It provides Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and Neonatal hyperbilirubinemia, as well as for prevention and cure of low-density-lipoproteinemia. The company also offers Human Hepatitis B Immunoglobulin for the prevention of measles and contagious hepatitis; Human Immunoglobulin and Human Immunoglobulin for Intravenous Injection products for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides Injection as a cure for various original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and a range of cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it provides Human Rabies Immunoglobulin primarily for passive immunity from bites or claws by rabies, or other infected animals; and Human Tetanus Immunoglobulin for the prevention and therapy of tetanus. The company's products under development comprise Human Prothrombin Complex Concentrate; Human Coagulation Factor VIII; Human Hepatitis B Immunoglobulin (PH4) for Intravenous Injection; Human Fibrinogen, Varicella Hyperimmune Globulins; and Human Immunoglobulin for Intravenous Injection. It primarily sells its products to hospitals and inoculation centers directly and through distributors in the People's Republic of China. The company is based in Taian City, the People's Republic of China.